Posted by Michael Wonder on 10 Oct 2017
The lifecycle of a rare disease cancer drug
10 October 2017 - One pharma company’s medicine illustrates how firms can benefit from different layers of market-exclusivity protections.
Pharmaceutical company Novartis has earned $50.42 billion from its cancer drug Glivec since 2001, using a variety of market-exclusivity protections to shield the medication from competition.
The drug was licensed for six different rare diseases, earning additional protections in each instance. By later withdrawing these protections, Novartis could also secure additional protections to reap back the lost market exclusivity while the drug was still in development and for testing in children.
